Selected Publications

Medical Research Council Renal Cancer Collaborators. Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Lancet 1999; 353: 14-17.

International collaboration of trialists on behalf of the Medical Research Council Advanced Bladder Cancer Working Party, EORTC Genito-Urinary Group, Australian Bladder Cancer Study Group, National Cancer Institute of Canada Clinical Trials Group, Finnbladder, Norwegian Bladder Cancer Study Group, and Club Urologico Espanol de Tratamiento Oncologico (CUETO) group. Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. Lancet 1999; 354: 533-540.

de Wit R, Roberts JT, Wilkinson PM, de Mulder PHM, Mead GM, Foss SD, Cook P, de Prijck L, Stenning S and Collette L. Equivalence of 3 BEP versus 4 cycles and of the 5 day schedule versus 3 days per cycle in good prognosis germ cell cancer, a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council. J Clin Oncol 2001;19: 1629-1640

Thatcher N, Girling DJ, Hopwood P, Sambrook RJ, Qian W, Stephens RJ for the Medical Research Council Lung Cancer Working Party. Improving survival without reducing quality of life in small-cell lung cancer patients by increasing the dose-intensity of chemotherapy with granulocyte colony- stimulating factor support: results of a British Medical Research Council multicenter randomized trial. Journal of Clinical Oncology 2000; 18: 395-404.

MRC Brain Tumour Working Party. Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma: A MRC Trial. Journal of Clinical Oncology 2001;19(2):509-18.